Growth Hormone Deficiency - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 111 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Growth Hormone Deficiency - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Growth Hormone Deficiency - Pipeline Review, H2 2014', provides an overview of the Growth Hormone Deficiency's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Growth Hormone Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Growth Hormone Deficiency and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Growth Hormone Deficiency
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Growth Hormone Deficiency and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Growth Hormone Deficiency products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Growth Hormone Deficiency pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Growth Hormone Deficiency
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Growth Hormone Deficiency pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Growth Hormone Deficiency Overview 9
Therapeutics Development 10
Pipeline Products for Growth Hormone Deficiency - Overview 10
Pipeline Products for Growth Hormone Deficiency - Comparative Analysis 11
Growth Hormone Deficiency - Therapeutics under Development by Companies 12
Growth Hormone Deficiency - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Growth Hormone Deficiency - Products under Development by Companies 18
Growth Hormone Deficiency - Companies Involved in Therapeutics Development 19
Teva Pharmaceutical Industries Limited 19
OPKO Health, Inc. 20
Access Pharmaceuticals, Inc. 21
AEterna Zentaris Inc. 22
Flamel Technologies S.A. 23
Emisphere Technologies, Inc. 24
HanAll Biopharma Co., Ltd. 25
LG Life Sciences, Ltd. 26
CJ CheilJedang Corp. 27
Critical Pharmaceuticals Limited 28
Aileron Therapeutics, Inc. 29
Ambrx, Inc. 30
Braasch Biotech LLC 31
Versartis, Inc. 32
Genexine, Inc. 33
Bolder Biotechnology, Inc. 34
Ascendis Pharma A/S 35
Pfenex Inc. 36
Delpor, Inc. 37
Inbiopro Solutions Pvt. Ltd. 38
Hanmi Pharmaceuticals, Co. Ltd. 39
Biogenomics Limited 40
XL-protein GmbH 41
Growth Hormone Deficiency - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Target 43
Assessment by Mechanism of Action 45
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
macimorelin acetate - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
somatropin SR - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
MOD-4023 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
somatropin - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
MOD-4023 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ARX-201 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
ACP-001 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
HM-10560A - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
albutropin - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
SYN-20100504RU - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
somatropin - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
GXH-9 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
somatropin - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
HL-032 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
somatropin - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
ALRN-5281 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
CJ-40002 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
somatropin biobetter - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
somatropin biobetter - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
CP-016 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
CobOral hGH - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
BBT-031 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
somatropin biosimilar - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
IBPB-003HH - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
somatropin biosimilar - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Vaccine For Growth Hormone Deficiencies - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
XL-020 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
somatropin - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Growth Hormone Deficiency - Recent Pipeline Updates 88
Growth Hormone Deficiency - Dormant Projects 100
Growth Hormone Deficiency - Discontinued Products 101
Growth Hormone Deficiency - Product Development Milestones 102
Featured News & Press Releases 102
Jun 30, 2014: Amunix Congratulates Versartis on Its Positive Phase 2a Results With VRS-317 102
Jun 27, 2014: OPKO Granted Patent from European Patent Office for Lagova 102
Jun 25, 2014: Strong Data from Lagova Phase II Clinical Study Presented during Webcast 103
Jun 23, 2014: OPKO Announces Positive Interim Six-Month Lagova (hGH-CTP) Phase 2 Data in Pediatric Growth Hormone Deficiency Disorder 104
Jun 23, 2014: Versartis Presents Positive Six Month VRS-317 Phase 2a Clinical Study Results 105
Jun 09, 2014: Versartis to Hold Conference Call to Discuss Six Month VRS-317 Phase 2a VERTICAL Clinical Trial Results 106
May 20, 2014: Data Supporting Once-Weekly Dosing of hGH-CTP in Growth Hormone Deficient Pediatric Population to Be Presented at the 2014 ICE/ENDO Meeting 107
May 20, 2014: Theratechnologies Inc.: Update on Availability of EGRIFTA in the United States 107
May 19, 2014: Versartis Selects Comprehend Systems 108
Apr 08, 2014: Critical Pharmaceuticals Receives Notice of Allowance from US Patent and Trademark Office for Intranasal Growth Hormone 108
Appendix 110
Methodology 110
Coverage 110
Secondary Research 110
Primary Research 110
Expert Panel Validation 110
Contact Us 111
Disclaimer 111

List of Tables
Number of Products under Development for Growth Hormone Deficiency, H2 2014 10
Number of Products under Development for Growth Hormone Deficiency - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Development by Companies, H2 2014 (Contd..1) 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Growth Hormone Deficiency - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 19
Growth Hormone Deficiency - Pipeline by OPKO Health, Inc., H2 2014 20
Growth Hormone Deficiency - Pipeline by Access Pharmaceuticals, Inc., H2 2014 21
Growth Hormone Deficiency - Pipeline by AEterna Zentaris Inc., H2 2014 22
Growth Hormone Deficiency - Pipeline by Flamel Technologies S.A., H2 2014 23
Growth Hormone Deficiency - Pipeline by Emisphere Technologies, Inc., H2 2014 24
Growth Hormone Deficiency - Pipeline by HanAll Biopharma Co., Ltd., H2 2014 25
Growth Hormone Deficiency - Pipeline by LG Life Sciences, Ltd., H2 2014 26
Growth Hormone Deficiency - Pipeline by CJ CheilJedang Corp., H2 2014 27
Growth Hormone Deficiency - Pipeline by Critical Pharmaceuticals Limited, H2 2014 28
Growth Hormone Deficiency - Pipeline by Aileron Therapeutics, Inc., H2 2014 29
Growth Hormone Deficiency - Pipeline by Ambrx, Inc., H2 2014 30
Growth Hormone Deficiency - Pipeline by Braasch Biotech LLC, H2 2014 31
Growth Hormone Deficiency - Pipeline by Versartis, Inc., H2 2014 32
Growth Hormone Deficiency - Pipeline by Genexine, Inc., H2 2014 33
Growth Hormone Deficiency - Pipeline by Bolder Biotechnology, Inc., H2 2014 34
Growth Hormone Deficiency - Pipeline by Ascendis Pharma A/S, H2 2014 35
Growth Hormone Deficiency - Pipeline by Pfenex Inc., H2 2014 36
Growth Hormone Deficiency - Pipeline by Delpor, Inc., H2 2014 37
Growth Hormone Deficiency - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 38
Growth Hormone Deficiency - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014 39
Growth Hormone Deficiency - Pipeline by Biogenomics Limited, H2 2014 40
Growth Hormone Deficiency - Pipeline by XL-protein GmbH, H2 2014 41
Assessment by Monotherapy Products, H2 2014 42
Number of Products by Stage and Target, H2 2014 44
Number of Products by Stage and Mechanism of Action, H2 2014 46
Number of Products by Stage and Route of Administration, H2 2014 48
Number of Products by Stage and Molecule Type, H2 2014 50
Growth Hormone Deficiency Therapeutics - Recent Pipeline Updates, H2 2014 88
Growth Hormone Deficiency - Dormant Projects, H2 2014 100
Growth Hormone Deficiency - Discontinued Products, H2 2014 101